27 Jun 2022 | 02:45 PM GMT

DTx-generated RWD: What is the value for Pharma?

About this Meeting

Real-world data (RWD) can be highly valuable to pharma companies; with several use cases from drug discovery and development to drug market access, label extensions, and understanding how their drugs and competitors are used in real life. While RWD can come from many sources, digital therapeutics (DTx) are proving a rich source. Aside from delivering therapies, DTx solutions are excellent data gathering tools that pharma could use to improve many aspects of their business. Join us in this meeting where we will deep dive into the value of DTx-generated RWD for pharma companies. We will talk about: 
  • What are the best use cases (e.g. drug market access, drug discovery and development, label extension, real-life use of drugs, etc.)? 
  • How can DTx companies leverage the RWD they generate as a new offering to their corporate clients? Is selling this anonymized data a feasible revenue stream for DTx companies? 
  • Are pharma companies currently using this data? Even though they see the potential, they are usually risk-averse, especially when using this data for drug discovery and development. How can companies convince pharma that the benefits outweigh the risks? 
  • What are the pharma’s quality standards for DTx-generated RWD? Do DTx companies meet these standards?